Immunobiology of IL-6 — Tocilizumab (humanised anti-IL-6 receptor antibody) for the treatment of rheumatoid arthritis

  • Yoshiyuki Ohsugi
  • Tadamitsu Kishimoto
Part of the Progress in Inflammation Research book series (PIR)


The cloning of IL-6 cDNA in 1986 revealed that IL-6 is a multifunctional cytokine that plays important roles in the immunopathogenesis of rheumatoid arthritis (RA). A close relationship was observed between IL-6 levels in the synovial compartment and disease activity in RA patients, and overproduction of IL-6 could readily explain the abnormal laboratory findings and clinical symptoms seen in these patients. IL-6 therefore appeared to be a worthwhile and attractive therapeutic target for RA. In practice, blockage of IL-6 signalling by a humanised anti-IL-6 receptor antibody [tocilizumab (TCZ); also known as MRA] has been found to be very effective in the treatment of patients with RA. In recent Japanese Phase III clinical studies in RA patients, TCZ clearly prevented radiographic progression of joint destruction and greatly improved signs and symptoms. Very interestingly and importantly, this therapy has also proved quite effective at improving fever, fatigue and anaemia. No serious adverse events have been reported. At present, several international clinical studies of TCZ are ongoing in more than 4000 patients with active RA in 41 countries. The results are continuing to confirm the efficacy and safety of TCZ in the treatment of patients with RA.


Rheumatoid Arthritis Patient Receptor Antibody Active Rheumatoid Arthritis Cardiac Myxoma Severe Active Rheumatoid Arthritis 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Kishimoto T (1989) The biology of interleukin-6. Blood 74: 1–10PubMedGoogle Scholar
  2. 2.
    Kishimoto T (2005) Interleukin-6: From basic science to medicine-40 years in immunology. Annu Rev Immunol 23: 1–21PubMedCrossRefGoogle Scholar
  3. 3.
    Gershwin ME, Ohsugi Y (eds) (2005) The immunobiology of IL-6. Clin Rev Allergy Immunol 28: 177–269Google Scholar
  4. 4.
    Nishimoto N, Kishimoto T (2006) Interleukin 6: from bench to bedside. Nat Clin Pract Rheumatol 2: 619–626PubMedCrossRefGoogle Scholar
  5. 5.
    Gauldie J, Richards C, Harnish D et al (1987) Interferon β/B-cell stimulatory factor type 2 shares identity with monocyte-derived hepatocyte-stimulating factor and regulates the major acute phase protein response in liver cells. Proc Natl Acad Sci USA 84: 7251–55PubMedCrossRefGoogle Scholar
  6. 6.
    Andus T, Geiger T, Hirano T et al (1987) Recombinant human B cell stimulatory factor 2 (BSF-2/IFN-β2) regulates β-fibrinogen and albumin mRNA levels in Fao-9 cells. FEBS Lett 221: 18–22PubMedCrossRefGoogle Scholar
  7. 7.
    Kopf M, Baumann H, Freer G et al (1994) Impaired immune and acute-phase responses in interleukin-6-deficient mice. Nature 368: 339–4PubMedCrossRefGoogle Scholar
  8. 8.
    Imazeki I, Saito H, Hasegawa M et al (1998) IL-6 functions in cynomolgus monkeys blocked by a humanized antibody to human IL-6 receptor. Int J Immunopharmacol 20: 345–357PubMedCrossRefGoogle Scholar
  9. 9.
    Hirano T, Yasukawa K, Harada H et al (1986) Complementary DNA for a novel human interleukin (BSF-2) that induces B lymphocytes to produce immunoglobulin. Nature 324: 73–76PubMedCrossRefGoogle Scholar
  10. 10.
    Yamasaki K, Taga T, Hirata Y et al (1988) Cloning and expression of the human interleukin-6 (BSF-2/IFN beta 2) receptor. Science 241: 825–828PubMedCrossRefGoogle Scholar
  11. 11.
    Taga T, Hibi M, Hirata Y et al (1989) Interleukin-6 triggers the association of its receptor with a possible signal transducer, gp130. Cell 58: 573–581PubMedCrossRefGoogle Scholar
  12. 12.
    Hibi M, Murakami M, Saito M et al (1990) Molecular cloning and expression of an IL-6 signal transducer, gp130. Cell 63: 1149–57PubMedCrossRefGoogle Scholar
  13. 13.
    Murakami M, Narazaki M, Hibi M et al (1991) Critical cytoplasmic region of the interleukin 6 signal transducer gp130 is conserved in the cytokine receptor family. Proc Natl Acad Sci USA 88: 11349–53PubMedCrossRefGoogle Scholar
  14. 14.
    Murakami M, Hibi M, Nakagawa N et al (1993) IL-6-induced homodimerization of gp130 and associated activation of a tyrosine kinase. Science 260: 1808–10PubMedCrossRefGoogle Scholar
  15. 15.
    Varghese JN, Moritz RL, Lou MZ et al (2002) Structure of the extracellular domains of the human interleukin-6 receptor 0#x03B1-chain. Proc Natl Acad Sci USA 99: 15959–64PubMedCrossRefGoogle Scholar
  16. 16.
    Skiniotis G, Boulanger MJ, Garcia KC, Walz T (2005) Signaling conformations of the tall cytokine receptor gp130 when in complex with IL-6 and IL-6 receptor. Nat Struct Mol Biol 12: 545–51PubMedCrossRefGoogle Scholar
  17. 17.
    Ip NY, Nye SH, Boulton TG et al (1992) CNTF and LIF act on neuronal cells via shared signalling pathways that involve the IL-6 signal transducing receptor component gp130. Cell 69: 1121–32PubMedCrossRefGoogle Scholar
  18. 18.
    Gearing DP, Comeau MR, Friend DJ et al (1992) The IL-6 signal transducer, gp130: An oncostatin M receptor and affinity converter for the LIF receptor. Science 255: 1434–37PubMedCrossRefGoogle Scholar
  19. 19.
    Liu J, Modrell B, Aruffo A et al (1992) Interleukin-6 signal transducer gp130 mediates oncostatin M signaling. J Biol Chem 267: 16763–66PubMedGoogle Scholar
  20. 20.
    Yin T, Taga T, Tsang ML et al (1993) Involvement of IL-6 signal transducer gp130 in IL-11-mediated signal transduction. J Immunol 151: 2555–61PubMedGoogle Scholar
  21. 21.
    Hirano T, Taga T, Nakano N et al (1985) Purification to homogeneity and characterization of human B-cell differentiation factor (BCDF or BSFp-2). Proc Natl Acad Sci USA 82: 5490–94PubMedCrossRefGoogle Scholar
  22. 22.
    Jourdan M, Bataille R, Seguin J et al (1990) Constitutive production of interleukin-6 and immunologic features in cardiac myxomas. Arthritis Rheum 33: 398–402PubMedCrossRefGoogle Scholar
  23. 23.
    Yoshizaki K, Matsuda T, Nishimoto N et al (1989) Pathogenic significance of interleukin-6 (IL-6/BSF-2) in Castleman’s disease. Blood 74: 1360–67PubMedGoogle Scholar
  24. 24.
    Hirano T, Matsuda T, Turner M et al (1988) Excessive production of interleukin 6/B cell stimulatory factor-2 in rheumatoid arthritis. Eur J Immunol 18: 1797–801PubMedCrossRefGoogle Scholar
  25. 25.
    Tak PP, Smeets TJ, Daha MR et al (1997) Analysis of the synovial cell infiltrate in early rheumatoid synovial tissue in relation to local disease activity. Arthritis Rheum 40: 217–25PubMedCrossRefGoogle Scholar
  26. 26.
    Sato K, Tsuchiya M, Saldanha J et al (1993) Reshaping a human antibody to inhibit the interleukin-6-dependent tumor cell growth. Cancer Res 53: 851–6PubMedGoogle Scholar
  27. 27.
    Nishimoto N, Sasai M, Shima Y et al (2000) Improvement in Castleman’s disease by humanized anti-interleukin-6 receptor antibody therapy. Blood 95: 56–61PubMedGoogle Scholar
  28. 28.
    Nishimoto N, Kanakura Y, Aozasa K et al (2005) Humanized anti-interleukin-6 receptor antibody treatment of multicentric Castleman’s disease. Blood 106: 2627–32PubMedCrossRefGoogle Scholar
  29. 29.
    Ohshima S, Saeki Y, Mima T et al (1998) Interleukin 6 plays a key role in the development of antigen-induced arthritis. Proc Natl Acad Sci USA 95: 8222–26PubMedCrossRefGoogle Scholar
  30. 30.
    Sakaguchi N, Takahashi T, Hata H et al (2003) Altered thymic T-cell selection due to a mutation of the ZAP-70 gene causes autoimmune arthritis in mice. Nature 426: 454–60PubMedCrossRefGoogle Scholar
  31. 31.
    Hata T, Sakaguchi N, Yoshitomi H et al (2004) Distinct contribution of IL-6, TNF-0#x03B1;, IL-1, and IL-10 to T cell-mediated spontaneous autoimmune arthritis in mice. J Clin Invest 114: 582–88PubMedGoogle Scholar
  32. 32.
    Nishimoto N, Yoshizaki K, Maeda K et al (2003) Toxicity, pharmacokinetics, and dose finding study of repetitive treatment with humanized anti-interleukin 6 receptor antibody, MRA, in rheumatoid arthritis — Phase I/II clinical study. J Rheumatol 30: 1426–35PubMedGoogle Scholar
  33. 33.
    Choy EH, Isenberg DA, Garrood T et al (2002) Therapeutic benefit after blocking interleukin-6 activity in rheumatoid arthritis with an anti-interleukin-6 receptor monoclonal antibody. Arthritis Rheum 46: 3143–50PubMedCrossRefGoogle Scholar
  34. 34.
    Nishimoto N, Yoshizaki K, Miyasaka N et al (2004) Treatment of rheumatoid arthritis with humanized anti-interleukin-6 receptor antibody: a multicenter, double-blind, placebo-controlled trial. Arthritis Rheum 50: 1761–69PubMedCrossRefGoogle Scholar
  35. 35.
    Maini RN, Taylor PC, Szechinski J et al (2006) Double-blind randomized controlled clinical trial of the interleukin-6 receptor antagonist, tocilizumab, in European patients with rheumatoid arthritis who had an incomplete response to methotrexate. Arthritis Rheum 54: 2817–29PubMedCrossRefGoogle Scholar
  36. 36.
    Ogawa J, Harigai M, Akashi T et al (2006) Exacerbation of chronic active Epstein-Barr virus infection in a patient with rheumatoid arthritis receiving humanised anti-interleukin-6 receptor monoclonal antibody. Ann Rheum Dis 65: 1667–9PubMedCrossRefGoogle Scholar
  37. 37.
    Nishimoto N, Hashimoto J, Miyasaka N et al (2007) Study of active controlled monotherapy used for rheumatoid arthritis, an IL-6 inhibitor (SAMURAI): Evidence of clinical and radiographic benefit from an X-ray reader-blinded randomized, controlled trial of tocilizumab. Ann Rheum Dis 66: 1162–7PubMedCrossRefGoogle Scholar
  38. 38.
    Smolen JS, Beaulieu A, Rubbert-Roth A et al (2008) Effect of interleukin-6 inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study) A double-blind, placebo-controlled, randamized trial. Lancet 371: 987–97PubMedCrossRefGoogle Scholar
  39. 39.
    Nemeth E, Valore EV, Territo M et al (2003) Hepcidin, a putative mediator of anemia of inflammation, is a type II acute-phase protein. Blood 101: 2461–3PubMedCrossRefGoogle Scholar
  40. 40.
    Nemeth E, Rivera S, Gabayan V et al (2004) IL-6 mediates hypoferremia of inflammation by inducing the synthesis of the iron regulatory hormone hepcidin. J Clin Invest 113: 1271–6PubMedGoogle Scholar
  41. 41.
    Lee P, Peng H, Galbart T et al (2005) Regulation of hepcidin transcription by interleukin-1 and interleukin-6. Proc Natl Acad Sci USA 102: 1906–10PubMedCrossRefGoogle Scholar
  42. 42.
    Nemeth E, Ganz T (2006) Regulation of iron metabolism by hepcidin. Annu Rev Nutr 26: 323–42PubMedCrossRefGoogle Scholar
  43. 43.
    Sasaki A, Yasukawa H, Shouda T et al (2000) CIS/SOCS-3 suppresses erythropoietin (EPO) signaling by binding the EPO receptor and JAK2. J Biol Chem 275: 29338–47PubMedCrossRefGoogle Scholar
  44. 44.
    Nakahara H, Song J, Sugimoto M et al (2003) Anti-interleukin-6 receptor antibody therapy reduces vascular endothelial growth factor production in rheumatoid arthritis. Arthritis Rheum 48: 1521–9PubMedCrossRefGoogle Scholar
  45. 45.
    Tamura T, Udagawa N, Takahashi N et al (1993) Soluble interleukin-6 receptor triggers osteoclast formation by interleukin-6. Proc Natl Acad Sci USA 90: 11924–8PubMedCrossRefGoogle Scholar
  46. 46.
    Mangan PR, Harrington LE, O’Quinn DB et al (2006) Transforming growth factor-_ induces development of the TH17 lineage. Nature 441: 231–234PubMedCrossRefGoogle Scholar
  47. 47.
    Bettelli E, Carrier Y, Gao W et al (2006) Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells. Nature 441: 235–238PubMedCrossRefGoogle Scholar
  48. 48.
    Veldhoen M, Hocking RJ, Atkins CJ et al (2006) TGFbeta in the context of an inflammatory cytokine milieu supports de novo differentiation of IL-17-producing T cells. Immunity 24: 179–189PubMedCrossRefGoogle Scholar
  49. 49.
    Kimura A, Naka T, Kishimoto T et al (2007) IL-6-dependent and independent pathways in the development of interleukin 17-producing T helper cells. Proc Natl Acad Sci USA 104: 12099–104PubMedCrossRefGoogle Scholar

Copyright information

© Birkhäuser Verlag Basel/Switzerland 2009

Authors and Affiliations

  • Yoshiyuki Ohsugi
    • 1
  • Tadamitsu Kishimoto
    • 2
  1. 1.Chugai Pharmaceutical Co. Ltd.TokyoJapan
  2. 2.Graduate School of Frontier BioscienceOsaka UniversityOsakaJapan

Personalised recommendations